GlassScriptPhysician profile
Michael T Happel
NPI 1215935275
$30,174.02
in general payments reported to CMS, 2019-2025
67 companies · $6,334 in 2025
The $6,334 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,036 · 2020: $3,226 · 2021: $4,730 · 2022: $4,488 · 2023: $4,249 · 2024: $4,111 · 2025: $6,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,610 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,890.04 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,610.00 |
| Education | $193.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,305.51 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $2,719.66 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $2,645.04 | 2023-2025 | Rexulti |
| Biogen, INC. | $1,641.10 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Ucb, INC. | $1,536.07 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Acadia Pharmaceuticals INC | $1,366.56 | 2019-2025 | Nuplazid |
| Eisai INC. | $1,206.24 | 2019-2025 | |
| Amgen INC. | $975.44 | 2019-2025 | Uplizna, Aimovig |
| Novartis Pharmaceuticals Corporation | $963.02 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $896.47 | 2020-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $856.34 | 2019-2025 | Ultomiris, Soliris |
| Celgene Corporation | $828.16 | 2021-2025 | Zeposia |
| Sk Life Science, INC. | $808.83 | 2020-2025 | |
| Pfizer INC. | $793.37 | 2021-2025 | |
| Neurelis, INC. | $727.16 | 2020-2025 | Valtoco |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $682.68 | 2020-2025 | Nourianz |
| Lilly USA, LLC | $659.72 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Jazz Pharmaceuticals INC. | $629.45 | 2019-2025 | |
| Argenx US, INC. | $401.89 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $398.65 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $387.85 | 2024-2025 | Ongentys, Crexont, Rytary |
| Janssen Pharmaceuticals, INC | $335.37 | 2020-2022 | |
| Csl Behring | $330.41 | 2019-2025 | Hizentra |
| Sunovion Pharmaceuticals INC. | $327.94 | 2019-2022 | |
| Lundbeck LLC | $302.24 | 2020-2025 | Vyepti, Rexulti |
| Upsher-Smith Laboratories LLC | $294.62 | 2020-2023 | |
| Ge Healthcare | $288.97 | 2019-2025 | |
| Mdd US Operations, LLC | $269.39 | 2019-2025 | Gocovri, Qelbree |
| Abbott Laboratories | $262.79 | 2021-2024 | Eterna |
| Biohaven Pharmaceuticals, INC. | $246.58 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $245.96 | 2019-2021 | |
| Genzyme Corporation | $236.44 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $226.61 | 2023-2024 | Aptiom |
| Biohaven Pharmaceutical Holding Company LTD. | $215.40 | 2022 | |
| Genentech USA, INC. | $202.52 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Adamas Pharmaceuticals, INC. | $199.04 | 2019-2021 | |
| Grifols USA, LLC | $147.46 | 2019-2023 | Gamunex-C |
| Tanabe Pharma America, INC. | $146.25 | 2019-2023 | |
| Boston Scientific Corporation | $144.85 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.43 | 2023-2025 | Hyqvia |
| Medtronic USA, INC. | $128.66 | 2019 | |
| Horizon Therapeutics Plc | $122.16 | 2022-2023 | Uplizna |
| Supernus Pharmaceuticals, INC. | $111.82 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.81 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $85.61 | 2024-2025 | Xeomin, Inbrija, Ampyra |
| Acorda Therapeutics, INC | $80.46 | 2019-2024 | Inbrija |
| Collegium Pharmaceutical, INC. | $70.31 | 2022 | |
| Arbor Pharmaceuticals, INC. | $61.84 | 2019-2022 | |
| Axsome Therapeutics, INC. | $52.85 | 2025 | Symbravo |
| Vanda Pharmaceuticals INC. | $32.15 | 2024-2025 | Fanapt |
| Alnylam Pharmaceuticals INC. | $30.85 | 2021-2023 | Givlaari |
| Astrazeneca Pharmaceuticals LP | $27.44 | 2024 | Wainua |
| Ipsen Biopharmaceuticals, INC | $26.73 | 2023 | Dysport |
| Ultragenyx Pharmaceutical INC. | $24.78 | 2024 | Dojolvi |
| Xeris Pharmaceuticals, INC. | $24.45 | 2023 | Keveyis |
| Promius Pharma LLC | $24.26 | 2019 | |
| Nevro Corp. | $22.54 | 2019 | |
| Strongbridge US INC. | $21.45 | 2020 | |
| Janssen Biotech, INC. | $19.28 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $17.77 | 2020 | |
| Avion Pharmaceuticals | $17.58 | 2023 | Dhivy |
| Grt US Holding, INC. | $17.04 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.90 | 2025 | Horizant |
| Kedrion Biopharma, INC. | $15.71 | 2025 | Albuked, Koate, Rhogam Ultra-Filtered Plus |
| Kedrion Biopharma INC. | $15.22 | 2019 | |
| Assertio Therapeutics, INC. | $12.50 | 2019 | |
| Zyla Life Sciences, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Happel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.